Composition for preventing or treating coronavirus infectious disease comprising hotspot-oriented peptide-nucleic acids hybrid
A peptide-nucleic acid hybrid molecule mimicking hACE2 effectively neutralizes SARS-CoV-2 variants by maintaining strong binding affinity to the spike protein's RBD, addressing the challenge of evasion mutations in existing antiviral agents.
Patent Information
- Application Number
- KR1020230044897
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2022-04-27
- Filing Date
- 2023-04-05
- Publication Date
- 2026-11-06
- Estimated Expiration
- 2043-04-05
AI Technical Summary
Existing antiviral agents fail to effectively neutralize SARS-CoV-2 variants due to evasion mutations that enhance binding interactions with host cell receptors, leading to reduced efficacy in blocking viral infection.
Development of a peptide-nucleic acid hybrid molecule that mimics the host cell receptor hACE2, specifically binding to the RBD of the spike protein, maintaining strong affinity despite mutations, and inhibiting viral entry.
The hybrid molecule effectively blocks SARS-CoV-2 variants by maintaining binding affinity and neutralizing the virus, including Alpha, Beta, Gamma, Delta, and Omicron variants, with potential applications in prevention and treatment of coronavirus infections.
Smart Images

Figure 112023038488943-PAT00011_ABST
Abstract
Description
Technology Field
[0001] The present invention relates to a composition for preventing or treating coronavirus infection, comprising a hotspot-derived peptide-nucleic acid hybrid molecule. Background Technology
[0003] When infection occurs, many viruses specifically recognize cell membrane proteins while entering host cells. For example, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is covered with thousands of spike proteins that bind strongly to the membrane receptor Human Angiotensin-Converting Enzyme 2 (hACE2), leading to membrane fusion. Viruses, including SARS-CoV-2, undergo mutations to increase infectivity, strengthening viral transmissibility over time and enabling immune evasion. Since SARS-CoV-2 was first reported in 2019, many variants have emerged, and variants of concern (VOCs) such as Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529) have arisen independently across different continents. The receptor binding domain (RBD) of the spike protein, which contributes to specific hACE2 recognition, is known to contain many common mutations. In particular, some positional mutations located in binding hotspots (e.g., N501Y) have been found to increase the binding affinity of RBD to the target hACE2, thereby increasing the infectivity of SARS-CoV-2.
[0004] The frequent emergence of variants can be a major obstacle to research on antiviral prevention and treatment. The use of affinity reagents can be an effective method for evading viral infection by blocking specific interactions between the virus and host cells. Numerous neutralizing affinity reagents have been developed to recognize various epitopes of the spike protein against SARS-CoV-2, some of which are known to partially overlap with the hACE2 contact surface. However, because evasion mutations cause structural changes in the spike protein, affinity reagents fail to specifically recognize binding sites, inevitably leading to reduced neutralization efficacy. As an alternative, non-competitive affinity reagents can be administered concurrently, and the U.S. Food and Drug Administration (FDA) announced the emergency use authorization of antibody cocktails such as REGN-COV2 due to the rapid emergence of SARS-CoV-2 variants. As viral variants accumulate evasion mutations, their binding interactions with host cell receptors become stronger, and they tend to develop enhanced resistance to antibody mixtures. Therefore, effective and efficient neutralizing agents must be developed by considering high affinity for the target virus and binding resistance to variants. Prior art literature
[0006] Korean Registered Patent Publication No. 10-2482994 The problem to be solved
[0007] Accordingly, inspired by the enhanced receptor recognition of viral variants, the inventors have novelly conceived the generation of receptor-mimicking synthetic reagents capable of strongly interacting with target viruses and their variants. Specifically, they focused on peptide motifs of host cell receptors that significantly contribute to binding free energy at the center of the virus-receptor interface. Without a stable but insoluble membrane-permeable domain, short hotspot peptides cannot maintain optimal binding ability to target viruses. In this process, they synergistically integrated with soluble nucleic acids capable of acting not only as structural stabilizers but also as binding cooperators. Numerous hotspot peptide-binding random nucleic acids (~10 14 Hybrid ligands can be easily prepared by selectively isolating and amplifying aptamer-like scaffolds that maximize hotspot interactions, which can lead to strong binding to viral variants.
[0008] In addition, the inventors successfully created an hACE2 receptor-mimicking hybrid ligand that directly interacts with the SARS-CoV-2 hotspot. The synergistic interaction between the hotspot peptide and the aptamer scaffold resulted in more effective binding to the RBD than reported affinity reagents (e.g., peptides, aptamers, or neutralizing antibodies), thereby efficiently blocking SARS-CoV-2. Furthermore, the invention was completed by confirming that the hotspot-binding hACE2 mimic maintained binding tolerance and showed no change in binding ability when recognizing various SARS-CoV-2 variants (Alpha, Beta, Gamma, Delta, Omicron).
[0009] Accordingly, the object of the present invention is a composition for the prevention or treatment of coronavirus infection comprising a peptide-nucleic acid hybrid molecule, wherein
[0010] The above peptide is a hotspot-derived peptide consisting of the amino acid sequence of SEQ ID NO. 15, and
[0011] The present invention provides a composition for preventing or treating coronavirus infection, wherein the nucleic acid comprises one nucleotide sequence selected from the group consisting of SEQ ID NOs 7, 8, 18, 19, and 20.
[0012] Another object of the present invention is to provide a composition for the prevention or treatment of coronavirus infection comprising a peptide-nucleic acid hybrid molecule prepared by a method comprising the following steps:
[0013] (a) a step of preparing a peptide-nucleic acid hybrid by site-specifically binding a hotspot-derived peptide consisting of the amino acid sequence of SEQ ID NO. 15 and a random nucleic acid library;
[0014] (b) a step of mixing and culturing the peptide-nucleic acid hybrid of step (a) with magnetic beads coated with the target protein; and
[0015] (c) A step of selecting peptide-nucleic acid hybrid molecules that bind to a target protein using a magnet.
[0016] Another objective of the present invention is a quasi-drug composition for preventing or inhibiting coronavirus infection comprising a peptide-nucleic acid hybrid molecule, wherein
[0017] The above peptide is a hotspot-derived peptide consisting of the amino acid sequence of SEQ ID NO. 15, and
[0018] The present invention provides a quasi-drug composition for preventing or suppressing coronavirus infection, wherein the nucleic acid comprises one nucleotide sequence selected from the group consisting of SEQ ID NOs 7, 8, 18, 19, and 20.
[0019] Another object of the present invention is an antiviral composition for coronavirus comprising a peptide-nucleic acid hybrid molecule, wherein
[0020] The above peptide is a hotspot-derived peptide consisting of the amino acid sequence of SEQ ID NO. 15, and
[0021] The present invention provides an antiviral composition for coronavirus, wherein the nucleic acid comprises one nucleotide sequence selected from the group consisting of SEQ ID NOs 7, 8, 18, 19, and 20.
[0022] Another object of the present invention is a composition for neutralizing coronavirus comprising a peptide-nucleic acid hybrid molecule, wherein
[0023] The above peptide is a hotspot-derived peptide consisting of the amino acid sequence of SEQ ID NO. 15, and
[0024] The present invention provides a composition for neutralizing coronavirus, wherein the nucleic acid comprises one nucleotide sequence selected from the group consisting of SEQ ID NOs 7, 8, 18, 19, and 20.
[0025] However, the technical problems that the present invention aims to solve are not limited to those mentioned above, and other unmentioned problems will be clearly understood by those skilled in the art to which the present invention belongs from the description below. means of solving the problem
[0027] The terms used in this specification are for illustrative purposes only and should not be interpreted as being limiting. Singular expressions include plural expressions unless the context clearly indicates otherwise. In this specification, terms such as "comprising" or "having" are intended to indicate the existence of the features, numbers, steps, actions, components, parts, or combinations thereof described in the specification, and should be understood as not precluding the existence or addition of one or more other features, numbers, steps, actions, components, parts, or combinations thereof.
[0028] Unless otherwise defined, all terms used herein, including technical or scientific terms, have the same meaning as generally understood by those skilled in the art to which the embodiments pertain. Terms such as those defined in commonly used dictionaries should be interpreted as having a meaning consistent with their meaning in the context of the relevant technology, and should not be interpreted in an ideal or overly formal sense unless explicitly defined in this application.
[0030] The present invention will be described in more detail below.
[0032] The present invention relates to a composition for the prevention or treatment of coronavirus infection comprising a peptide-nucleic acid hybrid molecule, wherein
[0033] The above peptide is a hotspot-derived peptide consisting of the amino acid sequence of SEQ ID NO. 15, and
[0034] The present invention provides a composition for preventing or treating coronavirus infection, wherein the nucleic acid comprises one nucleotide sequence selected from the group consisting of SEQ ID NOs 7, 8, 18, 19, and 20.
[0035] In the present invention, the peptide-nucleic acid hybrid molecule may be prepared through the following method, but is not limited thereto:
[0036] (a) a step of preparing a peptide-nucleic acid hybrid by site-specifically binding a hotspot-derived peptide consisting of the amino acid sequence of SEQ ID NO. 15 and a random nucleic acid library;
[0037] (b) a step of mixing and culturing the peptide-nucleic acid hybrid of step (a) with magnetic beads coated with the target protein; and
[0038] (c) A step of selecting peptide-nucleic acid hybrid molecules that bind to a target protein using a magnet.
[0039] In addition, the above method may further include, but is not limited to, the following steps:
[0040] (d) a step of selectively amplifying and replicating the nucleic acid portion of the peptide-nucleic acid hybrid molecule selected in step (c);
[0041] (e) a step of purifying the double-stranded DNA produced in step (d) by preparing it into single-stranded DNA using a nuclease; and
[0042] (f) a new random nucleic acid library composed of the single-stranded DNA of step (e) above, and a step of repeating the screening, amplification, and purification processes of steps (a) to (f).
[0043] In the present invention, the hotspot-derived peptide refers to a peptide residue that is considered to be highly associated with binding between a target protein and its receptor. The hotspot-derived peptide may be an amino acid of the binding site between the target protein and its receptor, and may be all or part of the amino acids involved in the binding site in the target protein sequence; or all or part of the amino acids involved in the binding site in the receptor sequence. In the present invention, a preferred embodiment of the hotspot-derived peptide used is a hACE2-derived hotspot peptide or an hACE2-derived RBD-binding peptide. Specifically, among the RBD contact residues of hACE2, a 7-amino acid fragment from L351 to R357 (LGKGDFR, SEQ ID NO. 15) was used as the hotspot-derived peptide. The hotspot-derived peptide may include a sequence having 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO. 15, but is not limited thereto.
[0044] In the present invention, the peptide-nucleic acid hybrid molecule can bind to the receptor binding domain (RBD) of the spike protein of the coronavirus. Furthermore, the peptide-nucleic acid hybrid molecule can exhibit excellent binding affinity with the RBD even in competition with RBD binding affinity reagents, and can exhibit excellent binding affinity even when a mutation occurs in the binding domain (RBD) of the spike protein. Accordingly, the peptide-nucleic acid hybrid molecule can inhibit the interaction between the RBD of the coronavirus and the hACE2 (human angiotensin-converting enzyme 2) receptor, neutralize the coronavirus, and neutralize the VOC (variant of concern) of the coronavirus, but is not limited thereto.
[0045] In the present invention, the RBD may be a wild type (Sequence No. 23) or a mutant type, and the mutant may include one or more selected from the group consisting of N501Y, E484K, K417N, K417T, T478K, L452R, E484A, G339D, S371L, S373P, S375F, N440K, S477N, G446S, Q493R, G496S, Q498R, and Y505H, but is not limited thereto.
[0047] [ RBD 서열: SARS- CoV -2 스파이크 단백질 중 [319-537] 아미노산 서열]
[0048] 319 - rv qptesivrfp nitnlcpf g e vfnatrfasv yawnrkrisn cvadysvlyn s a s f s tfkcy gvsptklndl cftnvyadsf virgdevrqi apgqtg k iad ynyklpddft gcviawnsn n ldskv g gnyn y l yrlfrksn lkpferdist eiyqag st pc ngv e gfncyf pl q sy g f q pt n gvg y qpyrv vvlsfellha patvcgpkks tnlvknk - 537(sequence number 23)
[0050] In the present invention, the peptide-nucleic acid hybrid molecule may satisfy the characteristics of nuclease resistance or serum stability, but is not limited thereto. Additionally, the peptide-nucleic acid hybrid molecule may be administered via various routes of administration depending on the therapeutic purpose and the method of formulation. For example, it may be administered by oral administration, subcutaneous injection, intraperitoneal administration, intramuscular injection, intrathecal (intradural) injection, sublingual administration, buccal mucosal administration, rectal insertion, vaginal insertion, ocular administration, ear administration, nasal administration, inhalation, spray through the mouth or nose, skin administration, or transdermal administration, but is preferably administered intravenously or respiratoryly, but is not limited thereto. Additionally, the peptide-nucleic acid hybrid molecule may be a hybrid ligand, a hotspot peptide-binding aptamer scaffold, a receptor-mimicking hybrid ligand, or an hACE2-mimicking hybrid ligand, but is not limited thereto.
[0051] In the present invention, the nucleic acid can be used to prepare a peptide-nucleic acid hybrid molecule by binding to a hotspot-derived peptide via a click reaction. Additionally, the nucleic acid can be isolated in vitro from a library of numerous nucleic acids that are site-specifically linked to the hotspot peptide by a repeating cycle of selection and amplification, and through the repeating cycle of selection and amplification, nucleic acids capable of providing a higher binding affinity to the peptide-nucleic acid hybrid molecule can be selected. Furthermore, the nucleic acid can increase the binding affinity and solubility for the binding site (RBD) between the spike protein of the peptide-nucleic acid hybrid molecule and its receptor, and can structurally stabilize the hACE2-derived RBD-binding peptide. Additionally, the nucleic acid may include one nucleotide sequence selected from the group consisting of SEQ ID NOs 7, 8, 18, 19, and 20, and the nucleic acid may include a sequence having 80%, 85%, 90%, 95%, 99%, or 100% identity with one nucleotide sequence selected from the group consisting of SEQ ID NOs 7, 8, 18, 19, and 20, but is not limited thereto. Additionally, the nucleic acid may be a hexinyl modified ssDNA, an aptamer scaffold, or a hotspot peptide-supported aptamer scaffold, but is not limited thereto.
[0052] In the present invention, an aptamer scaffold refers to a nucleic acid that combines two or more molecules to bind them into a functional unit and can specifically and strongly bind to a specific molecule. In one embodiment of the present invention, it is also called a peptide-supported aptamer scaffold, which is combined with a hotspot-derived peptide to have a virus neutralization function, and the hybrid molecule of the peptide and the aptamer scaffold can bind to the spike protein.
[0053] In the present invention, the coronavirus may be selected from one or more of the group consisting of human coronavirus 229E (HCoV-229E), human coronavirus OC43 (HCoV-OC43), severe acute respiratory syndrome coronavirus (SARS-CoV), human coronavirus NL63 (HCoV-NL63, New Haven coronavirus), human coronavirus HKU1, Middle East respiratory syndrome coronavirus (MERS-CoV), severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), and variants thereof, and the variant of SARS-Cov-2 may be any one selected from the group consisting of alpha (α), beta (β), gamma (γ), delta (δ), and omicron (ο) variants, but is not limited thereto.
[0054] In the present invention, "coronavirus" refers to a species of virus genus included in the order Nidovirales, family Coronavirusidae, subfamily Coronavirusinae, or Torovirinae. A coronavirus is a virus wrapped in +ssRNA and a helical symmetric nucleopeptide. Additionally, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the seventh coronavirus to infect humans to date, and the others are Human Coronavirus 229E (HCoV-229E), Human Coronavirus OC43 (HCoV-OC43), Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), Human Coronavirus NL63 (HCoV-NL63, New Haven Coronavirus), Human Coronavirus HKU1, and Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The proteins that contribute to the overall structure of coronaviruses are spikes, envelopes, and nucleocapsids. In the case of the SARS coronavirus, an extended binding receptor domain on the spike (spike(S)) mediates the virus's attachment to its cellular receptor, angiotensin-converting enzyme 2 (ACE2). Some coronaviruses (particularly members of the betacoronavirus subgroup) also possess a short spike, similar to a protein called antibody esterase. Coronaviruses can cause viral pneumonia or secondary bacterial pneumonia, and can also cause direct viral bronchitis or secondary bacterial bronchitis. A human coronavirus discovered in 2003 is the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), which causes Severe Acute Respiratory Syndrome (SARS) and induces upper and lower respiratory infections.
[0055] In addition, the term "SARS-CoV-2" used in the present invention refers to a novel coronavirus and represents a variant of SARS and MERS as an RNA virus. SARS-CoV-2 shares approximately 79.7% sequence identity with SARS and approximately 50% with MERS. However, in contrast to SARS and MERS, the spike glycoprotein of 2019-nCoV forms a structure in which one RBD domain protrudes upward, and as a result, exhibits a binding affinity 100 to 1,000 times stronger with the target receptor ACE2 (angiotensin). This strong binding affinity facilitates penetration into cells, thereby acting as a cause of increased infectivity.
[0056] Furthermore, in the present invention, the variant of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) has the same meaning as the COVID-19 variant. The variant is divided into major variants [Variant of Concern (VOC)] and other variants (Variant of Interest, VIO). To prevent the use of regional names and to facilitate smooth communication, the variants are named using the Greek alphabet (Alpha, Beta, Gamma, etc.). The major variant refers to a variant in which increased transmissibility or negative epidemiological changes have been confirmed, increased pathogenicity or changes in clinical disease severity have been confirmed, or a decrease in the efficacy of diagnostics, vaccines, or treatments has been confirmed. Currently, the VOC is the Omicron variant, and in the past, there were Alpha, Beta, Gamma, and Delta variants. Specifically, the Alpha (α) variant of SARS-Cov-2 was discovered in the UK in September 2020, and its phylogenetic classification is B.1.1.7. In addition, the above-mentioned SARS-Cov-2 beta (β) variant was discovered in South Africa in May 2020, and its phylogenetic classification is B.1.351. In addition, the above-mentioned SARS-Cov-2 gamma (γ) variant was discovered in Brazil in November 2020, and its phylogenetic classification is P.1. In addition, the above-mentioned SARS-Cov-2 delta (δ) variant was discovered in India in October 2020, and its phylogenetic classification is B.1.617.2. In addition, the above-mentioned SARS-Cov-2 omecro ( The variant was discovered in multiple countries in November 2021, and its phylogenetic classification is B.1.1.529.
[0057] In the present invention, the coronavirus infection may be a coronavirus respiratory infection. The viral respiratory infection may exhibit symptoms such as cough, sneezing, headache, nasal congestion, sore throat, diarrhea, discoloration of fingers or toes, conjunctivitis, high fever, wheezing, bronchitis, bronchiolitis, pneumonia, asthma, loss of smell and taste, and respiratory failure. If the coronavirus is Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COVID-2), the main symptoms may be fever and respiratory symptoms (cough, sore throat, shortness of breath), and in addition, may exhibit symptoms such as headache, muscle pain, hemoptysis, nausea, chills, chest pain, and diarrhea. Furthermore, the coronavirus infection may be Coronavirus Infection 19 (COVID-19).
[0059] The present invention provides a composition for preventing or treating coronavirus infection, comprising a peptide-nucleic acid hybrid molecule prepared by a method comprising the following steps:
[0060] (a) a step of preparing a peptide-nucleic acid hybrid by site-specifically binding a hotspot-derived peptide consisting of the amino acid sequence of SEQ ID NO. 15 and a random nucleic acid library;
[0061] (b) a step of mixing and culturing the peptide-nucleic acid hybrid of step (a) with magnetic beads coated with the target protein; and
[0062] (c) A step of selecting peptide-nucleic acid hybrid molecules that bind to a target protein using a magnet.
[0063] In the present invention, the method may further include, but is not limited to, the following steps:
[0064] (d) a step of selectively amplifying and replicating the nucleic acid portion of the peptide-nucleic acid hybrid molecule selected in step (c);
[0065] (e) a step of purifying the double-stranded DNA produced in step (d) by preparing it into single-stranded DNA using a nuclease; and
[0066] (f) a new random nucleic acid library composed of single-stranded DNA from step (e) above, and a step of repeating the screening, amplification, and purification processes of steps (a) to (f).
[0067] In the present invention, the method may further include, after step (a), a step of heat-denaturing and cooling the peptide-nucleic acid hybrid to induce 3D folding of the nucleic acid. Through this step, the hotspot peptide can be positioned in the correct location and orientation, and a stable 3D aptamer scaffold can be produced that maintains binding characteristics similar to or stronger than those of the receptor.
[0068] Step (a) above is a step of preparing a peptide-nucleic acid hybrid, wherein the hotspot-derived peptide may be a peptide in which any functional group that can be used in a click chemical reaction is attached to the C-terminus or N-terminus of the isolated hotspot-derived peptide, for example, a peptide in which one or more functional groups selected from the group consisting of azido lysine, azidobutanoic acid, and azidoacetic acid, azide, hexynyl, 5-octadiynyl, and alkyne are attached, preferably a peptide in which an azide is attached (tagged) to the C-terminus or N-terminus, and more preferably an azide-tagged LGKGDFR (L351 to R357, SEQ ID NO. 15) peptide, but is not limited thereto.
[0069] The random nucleic acid library of step (a) above may be a nucleic acid having any functional group that can be used in a click chemical reaction attached to the 5' end, for example, comprising a single-stranded nucleic acid to which one or more functional groups selected from the group consisting of hexynyl, 5-octadiynyl, alkyne, azido lysine, azidobutanoic acid, azidoacetic acid, and azide are attached, and preferably may be a nucleic acid to which hexynyl is attached to the 5' end, but is not limited thereto. Additionally, the functional groups attached to the hotspot-derived peptide and the nucleic acid library may be interchangeable. Furthermore, the random nucleic acid library may be characterized by comprising random nucleic acids having the following structure:
[0070] 5'-functional group-forward primer-[N x ] -Reverse Primer-3',
[0071] The above functional group is selected from the group consisting of hexynyl, 5-octadiynyl, alkyne, azido lysine, azidobutanoic acid, azidoacetic acid, and azide, and
[0072] Here, N is A, T, C, or G, and x is an integer from 25 to 100.
[0073] The length of the above random nucleic acid library is minimized to precisely bind to a target protein having a diameter of 10 nm or less, and may be a length that satisfies the suitability for maximizing the diversity of the library, but specifically, the number of base sequences of the above random nucleic acid library may be 55 to 130, 55 to 110, 55 to 90, 55 to 80, 60 to 130, 60 to 110, 60 to 90, 60 to 80, 65 to 130, 65 to 110, 65 to 90, 65 to 80, 65 to 75, or 70, but is not limited thereto.
[0074] In addition, the above x may be 25 to 100, 25 to 80, 25 to 60, 25 to 50, 30 to 100, 30 to 80, 30 to 60, 30 to 50, 35 to 100, 35 to 80, 35 to 60, 35 to 50, 35 to 45, or 40, but is not limited thereto.
[0075] In a preferred embodiment of the present invention, a forward primer represented by SEQ ID NO. 1 and a reverse primer represented by SEQ ID NO. 2 were used, and the random nucleic acid library includes random nucleic acids having the following structural formula: GGAAGAGATGGCGAC-N 40 -AGCTGATCCTGATGG.
[0076] Selective amplification of the nucleic acid portion of step (d) above may be performed using a forward primer with one or more functional groups selected from the group consisting of hexynyl, 5-octadiynyl, and alkyne attached to the 5' end, but is not limited thereto. Since the functional group is attached to the forward primer, all PCR products to be amplified may be produced with a functional group attached to the 5' end, thereby enabling site-specific binding via a click reaction, but is not limited thereto.
[0077] In the present invention, the hotspot-derived peptide and the single-stranded nucleic acid may be characterized by site-specific binding via a click reaction, but are not limited thereto. The click reaction may be a reaction in which the functional group of the hotspot-derived peptide and the functional group of the nucleic acid are chemically bonded to each other within a short period of time by cross-linking or copper-catalyzed cycloaddition, but are not limited thereto.
[0078] The pharmaceutical composition according to the present invention may further include a suitable carrier, excipient, and diluent commonly used in the manufacture of pharmaceutical compositions. The excipient may be one or more selected from the group consisting of, for example, diluents, binders, disintegrants, lubricants, adsorbents, humectants, film-coating materials, and controlled-release additives.
[0079] The pharmaceutical composition according to the present invention may be formulated and used in the form of external preparations such as powders, granules, sustained-release granules, enteric granules, liquids, eye drops, oxylic agents, emulsions, suspensions, ethanol tablets, troches, fragrances, limonene adzes, tablets, sustained-release tablets, enteric tablets, sublingual tablets, hard capsules, soft capsules, sustained-release capsules, enteric capsules, pills, tinctures, soft extracts, dry extracts, fluid extracts, injections, capsules, irrigation solutions, warning agents, lotions, pastes, sprays, inhalants, patches, sterile injectable solutions, or aerosols, according to conventional methods, and the external preparations may have formulations such as creams, gels, patches, sprays, ointments, warning agents, lotions, liniments, pastes, or cataplasms.
[0080] Carriers, excipients, and diluents that may be included in the pharmaceutical composition according to the present invention include lactose, dextrose, sucrose, oligosaccharide, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.
[0081] When formulating, it is prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants.
[0082] Excipients such as corn starch, potato starch, wheat starch, lactose, sucrose, glucose, fructose, D-mannitol, precipitated calcium carbonate, synthetic aluminum silicate, calcium monohydrogen phosphate, calcium sulfate, sodium chloride, sodium bicarbonate, refined lanolin, microcrystalline cellulose, dextrin, sodium alginate, methylcellulose, sodium carboxymethylcellulose, kaolin, urea, colloidal silica gel, hydroxypropyl starch, hydroxypropylmethylcellulose (HPMC) 1928, HPMC 2208, HPMC 2906, HPMC 2910, propylene glycol, casein, calcium lactate, primogel, etc., as additives to tablets, powders, granules, capsules, pills, and lozenges according to the present invention; Gelatin, gum arabic, ethanol, agar powder, cellulose phthalate, carboxymethylcellulose, calcium carboxymethylcellulose, glucose, purified water, sodium casein, glycerin, stearic acid, sodium carboxymethylcellulose, sodium methylcellulose, methylcellulose, microcrystalline cellulose, dextrin, hydroxycellulose, hydroxypropyl starch, hydroxymethylcellulose, refined shellac, starch paste, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinyl alcohol, polyvinylpyrrolidone, etc. may be used as binders, and hydroxypropylmethylcellulose, corn starch, agar powder, methylcellulose, bentonite, hydroxypropyl starch, sodium carboxymethylcellulose, sodium alginate, Calcium carboxymethylcellulose, calcium citrate, sodium lauryl sulfate, anhydrous silica, 1-hydroxypropylcellulose, dextran, ion exchange resin, polyvinyl acetate, formaldehyde-treated casein and gelatin, alginic acid, amylose, guar gum, sodium bicarbonate, polyvinylpyrrolidone, calcium phosphate, gelled starch, gum arabic, amylopectin, pectin, sodium polyphosphate, ethylcellulose, sucrose, magnesium aluminum silicate, D-sorbitol solution, hard anhydrous silica, etc. disintegrants;Lubricants such as calcium stearate, magnesium stearate, stearic acid, hydrogenated vegetable oil, talc, lycopodium pods, kaolin, petroleum jelly, sodium stearate, cocoa paste, sodium salicylate, magnesium salicylate, polyethylene glycol 4000, polyethylene glycol 6000, liquid paraffin, hydrogenated soybean oil (Lubri wax), aluminum stearate, zinc stearate, sodium lauryl sulfate, magnesium oxide, macrogol, synthetic aluminum silicate, anhydrous silica, higher fatty acids, higher alcohols, silicone oil, paraffin oil, polyethylene glycol fatty acid ether, starch, sodium chloride, sodium acetate, sodium oleate, dl-leucine, and hard anhydrous silica may be used.
[0083] As additives to the liquid formulation according to the present invention, water, dilute hydrochloric acid, dilute sulfuric acid, sodium citrate, monostearic acid sucroses, polyoxyethylene sorbitol fatty acid esters (tween esters), polyoxyethylene monoalkyl ethers, lanolin ethers, lanolin esters, acetic acid, hydrochloric acid, water ammonia, ammonium carbonate, potassium hydroxide, sodium hydroxide, prolamine, polyvinylpyrrolidone, ethylcellulose, sodium carboxymethylcellulose, etc. may be used.
[0084] In the syrup preparation according to the present invention, a solution of white sugar, other sugars or sweeteners, etc. may be used, and if necessary, flavorings, coloring agents, preservatives, stabilizers, suspending agents, emulsifiers, viscosity enhancers, etc. may be used.
[0085] Purified water may be used in the emulsion according to the present invention, and emulsifiers, preservatives, stabilizers, fragrances, etc. may be used as needed.
[0086] In the suspension agent according to the present invention, suspending agents such as acacia, tragacanthus, methylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, microcrystalline cellulose, sodium alginate, hydroxypropylmethylcellulose, HPMC 1828, HPMC 2906, and HPMC 2910 may be used, and surfactants, preservatives, stabilizers, coloring agents, and fragrances may be used as needed.
[0087] The injectable preparation according to the present invention comprises solvents such as distilled water for injection, 0.9% sodium chloride injection solution, Ringer's injection solution, dextrose injection solution, dextrose + sodium chloride injection solution, PEG, lactated Ringer's injection solution, ethanol, propylene glycol, non-volatile oils—sesame oil, cottonseed oil, peanut oil, soybean oil, corn oil, ethyl oleate, isopropyl myristate, and benzene benzoate; solubilizing agents such as sodium benzoate, sodium salicylate, sodium acetate, urea, urethane, monoethylacetamide, butazolidine, propylene glycol, tween, nijungtinamide, hexamine, and dimethylacetamide; and buffers such as weak acids and their salts (acetic acid and sodium acetate), weak bases and their salts (ammonia and ammonium acetate), organic compounds, proteins, albumin, peptone, and gums. It may include isotonic agents such as sodium chloride; stabilizers such as sodium bisulfite (NaHSO3), carbon dioxide gas, sodium metabisulfite (Na2S2O5), sodium sulfite (Na2SO3), nitrogen gas (N2), and ethylenediaminetetraacetic acid; sulfating agents such as sodium bisulfide 0.1%, sodium formaldehyde sulfoxylate, thiourea, disodium ethylenediaminetetraacetic acid, and sodium bisulfite acetone; non-inflammatory agents such as benzyl alcohol, chlorobutanol, procaine hydrochloride, glucose, and calcium gluconate; and suspending agents such as sodium CMC, sodium alginate, Tween 80, and aluminum monostearate.
[0088] The suppository according to the present invention comprises cocoa dough, lanolin, Witepsol, polyethylene glycol, glycerogelatin, methylcellulose, carboxymethylcellulose, a mixture of stearic acid and oleic acid, Subanal, cottonseed oil, peanut oil, palm oil, cocoa butter + cholesterol, lecithin, lanette wax, glycerol monostearate, Tween or Spandex, Imhausen, monollene (propylene glycol monostearate), glycerin, Adeps solidus, Buytyrum Tego-G, Cebes Pharma 16, hexalide base 95, Cotomar, Hydroccote SP, S-70-XXA, S-70-XX75 (S-70-XX95). Bases such as Hydrokote 25, Hydrokote 711, Idropostal, Massa estrarium (A, AS, B, C, D, E, I, T), Masa-MF, Masupol, Masupol-15, Neosupostal-N, Paramount-B, Suposiro (OSI, OSIX, A, B, C, D, H, L), suppository base type IV (AB, B, A, BC, BBG, E, BGF, C, D, 299), Supostal (N, Es), Wekovi (W, R, S, M, Fs), and Tegestor triglyceride base (TG-95, MA, 57) may be used.
[0089] Solid dosage forms for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid dosage forms are prepared by mixing at least one excipient, such as starch, calcium carbonate, sucrose or lactose, gelatin, etc., with the extract. In addition to simple excipients, lubricants such as magnesium styrate and talc are also used.
[0090] Liquid preparations for oral administration include suspensions, oral liquids, emulsions, and syrups; in addition to commonly used simple diluents such as water and liquid paraffin, they may contain various excipients, such as humectants, sweeteners, flavorings, and preservatives. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate.
[0091] The pharmaceutical composition according to the present invention is administered in a pharmaceutically effective amount. In the present invention, "pharmaceutically effective amount" means an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level may be determined according to factors including the type and severity of the patient's disease, drug activity, sensitivity to the drug, time of administration, route of administration and elimination rate, duration of treatment, concurrently used drugs, and other factors well known in the medical field.
[0092] The pharmaceutical composition according to the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered as a single or multiple doses. It is important to administer an amount that obtains maximum effect with a minimum amount without side effects by considering all the above-mentioned factors, and this can be easily determined by a person skilled in the art to which the present invention belongs.
[0093] The pharmaceutical composition of the present invention may be administered to an individual by various routes. All modes of administration are expected, for example, oral administration, subcutaneous injection, intraperitoneal administration, intramuscular injection, intrathecal (intradural) injection, sublingual administration, buccal mucosal administration, rectal insertion, vaginal insertion, ocular administration, ear administration, nasal administration, inhalation, spray through the mouth or nose, skin administration, transdermal administration, etc.
[0094] The pharmaceutical composition of the present invention is determined by the type of active ingredient drug, along with various relevant factors such as the disease to be treated, the route of administration, the patient's age, gender, weight, and the severity of the disease.
[0095] In the present invention, the term “individual” refers to a subject requiring treatment for a disease, and more specifically, to mammals such as humans or non-human primates, mice, rats, dogs, cats, horses, and cattle.
[0096] In the present invention, “administration” means providing a specific composition of the present invention to an individual by any appropriate method. In the present invention, “prevention” means any act of suppressing or delaying the onset of a target disease; “treatment” means any act of improving or beneficially altering the target disease and the associated metabolic abnormality symptoms by administering a pharmaceutical composition according to the present invention; and “improvement” means any act of reducing parameters related to the target disease, such as the severity of symptoms, by administering a composition according to the present invention.
[0098] The present invention relates to a quasi-drug composition for preventing or inhibiting coronavirus infection, comprising a peptide-nucleic acid hybrid molecule, wherein
[0099] The above peptide is a hotspot-derived peptide consisting of the amino acid sequence of SEQ ID NO. 15, and
[0100] The present invention provides a quasi-drug composition for preventing or inhibiting coronavirus infection, wherein the nucleic acid comprises one nucleotide sequence selected from the group consisting of SEQ ID NOs 7, 8, 18, 19, and 20.
[0101] In addition, the above-mentioned quasi-drugs may include external skin preparations and personal hygiene products. For example, they may be, but are not limited to, disinfectants, shower foams, mouthwash, wet wipes, detergent soaps, hand washes, or ointments.
[0102] When the above-described quasi-drug composition according to the present invention is used as a quasi-drug additive, the composition may be added as is or used together with other quasi-drugs or quasi-drug ingredients, and may be used appropriately according to conventional methods. The mixing amount of the active ingredient may be appropriately determined according to the purpose of use.
[0103] The quasi-drug composition of the present invention may, for example, be prepared in the form of a general emulsion formulation and a solubilized formulation. For example, it may have a formulation such as a lotion, cream, ointment, spray, oil gel, gel, oil, aerosol, or fogging agent, but it may be used without limitation as long as it exhibits the pest control inducing effect of the present invention. In addition, the quasi-drug composition may be used by appropriately incorporating, as necessary, oils, water, surfactants, humectants, lower alcohols having 1 to 4 carbon atoms, thickeners, chelating agents, colorants, preservatives, or fragrances that are generally incorporated into quasi-drug compositions into each formulation.
[0105] The present invention relates to an antiviral composition for coronavirus comprising a peptide-nucleic acid hybrid molecule, wherein
[0106] The above peptide is a hotspot-derived peptide consisting of the amino acid sequence of SEQ ID NO. 15, and
[0107] The present invention provides an antiviral composition for coronavirus, wherein the nucleic acid comprises one nucleotide sequence selected from the group consisting of SEQ ID NOs 7, 8, 18, 19, and 20.
[0108] In the present invention, “antiviral” means to weaken or eliminate the action of a virus that has invaded the body by inhibiting the proliferation of a virus within the body, and more specifically, means to inhibit the proliferation of a virus by inhibiting the nucleic acid synthesis process, gene expression process, or viral replication process of the virus, and in the present invention, the target is the coronavirus.
[0109] In the present invention, the antiviral composition may have antiviral activity against human coronavirus 229E (HCoV-229E), human coronavirus OC43 (HCoV-OC43), severe acute respiratory syndrome coronavirus (SARS-CoV), human coronavirus NL63 (HCoV-NL63, New Haven coronavirus), human coronavirus HKU1, Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2 or 2019 novel coronavirus or 2019-nCoV).
[0111] The present invention relates to a composition for neutralizing coronavirus comprising a peptide-nucleic acid hybrid molecule, wherein
[0112] The above peptide is a hotspot-derived peptide consisting of the amino acid sequence of SEQ ID NO. 15, and
[0113] The above nucleic acid provides a composition for neutralizing coronavirus, wherein the nucleic acid comprises one nucleotide sequence selected from the group consisting of SEQ ID NOs 7, 8, 18, 19, and 20.
[0114] The following descriptions regarding the composition for a quasi-drug for preventing or suppressing coronavirus infection, the composition for antiviral use against coronavirus, and the composition for neutralizing coronavirus may be applied in the same way as the descriptions in the previously described composition for preventing or treating coronavirus infection, and duplicate descriptions are omitted to avoid complexity in the specification. Effects of the invention
[0116] It was confirmed that the in vitro evolution-based hotspot-derived peptide-nucleic acid hybrid molecule produced by the manufacturing method of the present invention has a high binding affinity for the RBD of SARS-CoV-2 VOCs (alpha, beta, gamma, delta, and omichron), and in particular, it was confirmed that it showed the greatest binding resistance in the omichron, which is the most mutated. In addition, it was confirmed that the hybrid molecule has a high RBD binding affinity even in competition with RBD-binding nucleic acid aptamers, macrocyclic peptides, monoclonal antibodies, etc. Furthermore, as it showed excellent nuclease resistance and serum stability, it has excellent potential as a viral neutralizer not only against SARS-CoV-2 but also against viruses. Brief explanation of the drawing
[0118] Figure 1a illustrates the role of a nucleic acid scaffold in inducing stable binding between a hotspot peptide and a viral RBD. Figure 1b shows a schematic diagram of the in vitro evolution of a receptor-mimicking hybrid ligand composed of a hotspot peptide and an aptamer scaffold. Figure 2a shows the results of analyzing contact residues between the hACE2 receptor and SARS-CoV-2 RBD. Figure 2b shows the N501Y mutation of RBD, which has a higher binding affinity to hACE2. Figure 2c shows the results of a quantitative evaluation of RBD binding in the hotspot peptide binding round 7 (R7) pool (random DNA library bound to hotspot peptide (light gray), R7 ssDNA pool without hotspot peptide (dark gray), and R7 ssDNA pool bound to hotspot peptide (green)). Figure 3a shows the results of comparing the RBD binding fractions of R7-01, R7-02, R7-03, and hybrid random libraries. Figure 3b shows the results of analyzing the RBD binding affinity characteristics of R7-02 (RBD and serum albumin-coated beads (green and gray, respectively), bare beads (black)). Figure 3c shows the RBD binding affinity characteristics (K d This shows the results of analyzing the value. Figure 3d shows the energy-minimized structure of R7-02 bound to RBD through molecular docking simulation (LGKGDFR peptide (red), hACE2 (white), RBD (blue), aptamer scaffold (green)). Figures 3e and 3f show the results of analyzing competitive binding after co-culturing the hybrid ligand with RBD-binding nucleic acid aptamers (CoV2-RBD-1C, CoV2-6C3, Aptamer-1), macrocyclic peptides (Peptide 4), or monoclonal antibodies (P05Dhu, AM122). Figure 3g shows the equilibrium dissociation constant K of an RBD-binding nucleic acid aptamer (CoV2-RBD-1C, CoV2-6C3, Aptamer-1), macrocyclic peptide (Peptide 4), or monoclonal antibody (P05Dhu, AM122). d This shows the results of the value analysis. Figure 4a shows a schematic diagram and list of variants of alpha, beta, gamma, delta, and omicron VOCs (variants of concern). Figure 4b shows the K for alpha, beta, gamma, delta, and ohmicron VOCs of R7-02. d This shows the results of the value analysis. Figure 4c shows the results of analyzing the RBD binding fraction of R7-02 and various types of RBD binders (Aptamer-1, Peptide 4, P05DHu, and AM122) for wild-type and Omicron VOCs. Figure 4d shows the results of analyzing the binding fractions of R7-02 and various types of RBD binders (Aptamer-1, Peptide 4, P05DHu, and AM122) to wild-type and Omicron VOCs through flow cytometry. Figure 5a shows the inhibitory effect of R7-02 on RBD-hACE2 binding via ELISA (enzyme-linked immunosorbent assay). Figure 5b shows the results of confirming the inhibition rate of the RBD-hACE2 interaction of LGKGDFR peptide, R7-02 DNA domain, R7-02, random DNA library, and hACE2. Figure 5c shows a schematic diagram of a pseudotype SARS-CoV-2-based neutralization assay. Figures 5d and 5f show the results of observing pseudotype SARS-CoV-2 infected hACE2-293T using a confocal microscope (Figure 5d: LGKGDFR peptide, R7-02 DNA domain, R7-02; Figure 5f: CoV2-RBD-1C, CoV2-6C3, Aptamer-1, Peptide 4, P05Dhu, AM122). Figures 5e and 5g show the percentage of GFP-expressing pseudotype SARS-CoV-2 infected cells relative to total hACE2-293T cells (Figure 5e: LGKGDFR peptide, R7-02 DNA domain, R7-02; Figure 5g: CoV2-RBD-1C, CoV2-6C3, Aptamer-1, Peptide 4, P05Dhu, AM122). Figure 5h shows the results of the analysis of nuclease stability of R7-02. Specific details for implementing the invention
[0119] Preferred embodiments are presented below to aid in understanding the present invention. However, the following embodiments are provided merely to facilitate a better understanding of the invention, and the scope of the invention is not limited by the following embodiments.
[0121] [실험방법]
[0122] 1. 실험 재료
[0123] DNA oligonucleotides were synthesized and purified at Bioneer (Korea). The sequences of all oligonucleotides used in the present invention are shown in Table 1 below. C-terminal (4-azidobutanoyl(lysine))-tagged LGKGDFR peptides (with and without N-terminal FITC modifications) were synthesized and purified at Peptron (Korea). EDC (1-ethyl-3-(3-365 dimethylaminopropyl) carbodiimide hydrochloride), NHS (N-hydroxysuccinimide), 1M magnesium chloride solution, human angiotensin-converting enzyme 2 (hACE2), bovine serum albumin (BSA), high glucose DMEM, Tween-20, DMSO (dimethyl sulfoxide), THPTA (tris(3-hydroxypropyl-triazolylmethyl)amine)), and copper(II) sulfate pentahydrate were purchased from Sigma-Aldrich. L-Ascrobic acid sodium salt was purchased from Alfa Aesar. Lambda exonuclease enzyme and 10x lambda exonuclease buffer were purchased from Thermo Fisher Scientific. 1M Tris-HCl (pH 7.4) was purchased from Bioneer (Korea). 10x PBS, 8M urea solution, 10x TBE, and nuclease-free purified water were purchased from T&I (Korea). 1x PBSMT was used as the binding buffer (composed of 1x PBS, pH 7.4 containing 2.5 mM MgCl2 and 0.02% Tween-20 (v / v)). Wild-type, alpha (B.1.1.7), beta (B.1.351), gamma (P.1), and delta (B.1.617.2) SARS-CoV-2 RBDs were expressed and purified. Omicron (B.1.1.SARS-CoV-2 RBD from 529) was purchased from Abbexa (UK). Alexa-488-labeled monoclonal RBD-binding antibody (P05DHu) and the Alexa Fluor 488 microscale protein labeling kit were purchased from Invitrogen. Monoclonal RBD-binding antibody (AM122) was purchased from ACROBiosystems. A macrocyclic peptide (Peptide 4) containing N-terminal chloroacetyl-modified D-tyrosine was linearly synthesized at Peptron (Korea). 1 mg of linear peptide 4 was dissolved in 86 μL of DMSO with 3 μL of N,N-diisopropylethylamine to cyclize and incubated at 60°C for 24 hours.
[0125] ID Sequence (5' → 3') 서열번호 Forward primary [Hexynyl]GGAAGAGATGGCGAC 1 Primary reverse [Phosphate]CCATCAGGATCAGCT 2 Random library [Hexynyl]GGAAGAGATGGCGAC-N40-AGCTGATCCTGATGG 3 (HTS sequencing) forward primer AATGATACGGCGACCACCGAGATCTACACTTGGTGAGACACTCTTTCCCTACGACGCTCTTCCGATNNNNNNNGGAAGAGATGGCGAC 4 (HTS sequencing) reverse primer CAAGCAGAAGACGGCATACGAGATGTTCAGGTCTGACTGGAGTTCAGACGTGTGCTCTTCCGATNNNNNNCCATCAGGATCAGCT 5 R7-01DNA domain [Hexynyl]GGAAGAGATGGCGACCTCCACAACCGCTGATCGACGCAGATCTTGTGGGTAGCTGATCCTGATGG[FAM] 6 R7-02DNA domain [Hexynyl]GGAAGAGATGGCGACACGCAATCGTGGGTTGGGGATATAATGGTA AGCTGATCCTGATGG[FAM] 7 R7-02 (TAMRA)DNA domain [Hexynyl]GGAAGAGATGGCGACACGCAATCGTGGGTTGGGGATATAATGGTA AGCTGATCCTGATGG[TAMRA] 8 R7-03DNA domain [Hexynyl]GGAAGAGATGGCGACCACACCAAATCTGAGTCTACCCCATGAAGGAGCTGATCCTGATGG[FAM] 9 CoV2-RBD-1C [TAMRA]CAGCACCGACCTTGTGCTTTGGGAGTGCTGGTCCAAGGGCGTTAATGGACA 10 CoV2-6C3 [TAMRA]CGCAGCACCCAAGAACAAGGACTGCTTAGGATTGCGATAGGTTCGG 11 Aptamer-1 core [TAMRA]TCGAGTGGCTTGTTTGTAATGTAGGGTTCCGGTCGTGGGT 12 2'-O-Methyl, 2'-Fmodified R7-02 [Hexynyl]G(2'-OMe(G))(2'-OMe-(A))(2'-OMe(A))(2'-OMe(G))AGATGGCGACA CGCAATCGTGGTTGGGGATATAATGGTAAGCTGATCCT(2'-OMe-(G))(2'-OMe(A))(2'OMe(T))(2'-F(G))G[FAM] 13 Phosphorothioate (*)modified R7-02 [Hexynyl]G*G*A*A*GAGATGGCGACACGCAATCGTGGGTTGGGGATATAATGGTA AGCTGATCCTG*A*T*G*G[FAM] 14
[0127] 2. Azaid -tag hotspot peptide ( azide -tagged hotspot peptide) and Hexinyl strain ssDNA position-specific coupling between
[0128] For ultra-high efficiency copper catalyst alkyne-azide cycloaddition, 1 μL of a 50 mM aqueous copper(II) sulfate solution and 1.67 μL of a 150 mM aqueous THPTA solution were mixed 10 minutes prior to conjugation. 3 μL of DMSO, 1 μL of 10x PBS, 3 μL of a 0.1 mM aqueous hexinyl-modified ssDNA solution, 1 μL of a 2.5 mM azide-tagged LGKGDFR peptide, 2.67 μL of premix (copper(II) sulfate and THPTA), and 1 μL of a 500 mM aqueous sodium ascorbate solution (freshly prepared) were added in sequence and thoroughly mixed. The solution was shaken overnight at room temperature and purified by ethanol precipitation.
[0130] 3. peptide - ssDNA combination hybrid Check library
[0131] The formation of peptide-ssDNA conjugation was confirmed via fluorescence after conjugation with the FITC-modified azide-tagged LGKGDFR peptide. 1 μL of the reaction product (~50 ng), 7 μL of 8 M urea solution, and 1 μL of 6x loading dye were mixed and heat-denatured at 95 °C for 10 minutes. The denatured product was analyzed by electrophoresis on a 10% urea polyacrylamide gel at 300 V for 40 minutes in 1x TBE buffer and imaged using an Azure C600 (Azure Biosystems). An equal amount of unconjugated hexinyl-modified ssDNA library was stained with 10,000x SYBR gold staining dye (Invitrogen) and imaged simultaneously.
[0133] 4. HOLD (Hotspot-Oriented Ligand Display)
[0134] The peptide-nucleic acid hybrid library was heat-denatured at 95°C for 10 minutes and then rapidly cooled on ice to form the most stable 3D structure. Subsequently, the heat-treated hybrid library was incubated with RBD-coated beads at room temperature for 1 hour using gentle rotation. When preparing the RBD-coated beads, the target RBD was immobilized on Dynabeads M-270 carboxylic acid (Invitrogen) via the EDC-NHS coupling process using the manufacturer's protocol, and then quantified using the NanoOrange Protein Quantification Kit (Thermo Fisher Scientific). After incubation, the magnetic beads were thoroughly washed with 1x PBSMT to remove unbound hybrid molecules, and the magnetic bead-bound hybrid ligands were selectively separated using a DynaMag-2 magnet (Invitrogen). Only the DNA domains of the separated hybrid ligand candidates were PCR amplified using 5'-hexinyl-modified forward primers and 5'-phosphorylated reverse primers (Table 1 above). The optimal number of PCR cycles was determined by a pilot PCR process. PCR-amplified dsDNA was purified using the QIAquick PCR Purification Kit (Qiagen) and then digested with Lambda exonuclease to generate a hexinyl-modified ssDNA pool for the next hold round. The ssDNA was purified by phenol / chloroform extraction and ethanol precipitation, and quantified by UV-vis measurement at 260 nm. To provide a hybrid library pool of the same format for each hold round, the click reaction between the azide-tagged LGKGDFR peptide and the purified hexinyl-modified ssDNA pool was repeated for each hold round.
[0136] 5. Volume dilution challenge
[0137] The volume dilution challenge (VDC) technique was used to very efficiently remove unbound hybrid molecules. After 1 hour of incubation and subsequent washing of the bead-bound hybrid library, it was immediately diluted with increased volumes (100–500x) of 1x PBSMT and incubated for an additional 30 minutes to [remove] the high rate dissociation constant (k off Hybrid molecules that were easily separated during this process were removed using the value. After VDC, the beads were collected and washed three times with 200 μL of 1x PBSMT.
[0139] 6. High affinity hybrid DNA domain amplification that enriches ligands
[0140] A 100 μL PCR reaction mixture contained 5 units of tag polymerase (Taq polymerase, T&I, Korea), 0.5 μL of 0.1 mM 5'-hexinyl-modified forward primer and 5'-phosphorylated reverse primer, 8 μL of 10 mM dNTP (T&I, Korea), 2 μL of 10x PCR buffer (T&I, Korea), 10 μL of collected hybrid ligand, and additional nuclease-free purified water (up to 100 μL). The PCR reaction mixture was pre-denatured at 95 °C for 600 seconds, followed by a cycle of 30 seconds of denaturation at 95 °C, 30 seconds of annealing at 51 °C, and 60 seconds of extension at 72 °C. 5 μL of PCR mixture was collected and dissolved in a 10% polyacrylamide gel to determine the optimal number of PCR amplification cycles with minimized byproducts (pilot PCR). The DNA domains of the hybrid ligands collected in all rounds of HOLD were PCR amplified with the optimized number of cycles.
[0142] 7. ssDNA generation
[0143] After PCR amplification, hexinyl-modified double-stranded DNA (dsDNAs) was purified using the QIAquick PCR purification kit (Qiagen), and 2.5 μg of the purified dsDNA was digested in 50 μL with 5 units of lambda nuclease (Thermo Fisher Scientific). After incubating the mixture at 37°C for 10 minutes and at 80°C for 10 minutes, the hexinyl-modified ssDNA was purified by phenol / chloroform extraction and ethanol precipitation, and quantified by UV-vis measurement at 260 nm.
[0145] 8. Relative coupling analysis of R7 pools
[0146] After 7 rounds of hold, the relative binding ability of the hybrid ligand pools was compared. Equal amounts of peptide-nucleic acid hybrid libraries bound to the hotspot peptide, an R7 ssDNA pool without the hotspot peptide, and an R7 ssDNA pool bound to the hotspot peptide were heat-denatured at 95 °C for 10 minutes and then rapidly cooled on ice. After heat denaturation, the samples were challenged with RBD-coated magnetic beads at room temperature for 1 hour, followed by 3 washes with 1x PBSMT. The amount of RBD binding was analyzed by quantitative PCR (LightCycler 480, Roche). Each PCR reaction contained 10 μL of LightCycler 480 SYBR green I master (Roche), 0.1 μL of 0.1 mM forward and reverse primers, 2 μL of RBD-binding ligand, and 7 μL of nuclease-free purified water. Based on the previously obtained standard curve, the threshold period was estimated as the amount of RBD-bound ligand.
[0148] 9. High-throughput sequencing
[0149] After 7 rounds of selection, the enriched pool was PCR amplified with forward and reverse primers containing adapter sequences, and the optimized number of PCR cycles was determined by pilot PCR. These PCR products were purified using a gel extraction kit (Qiagen) and then sequenced using Illumina MiSeq Next Generation Sequencing from SYSGENLAB (Korea). The sequencing library was analyzed on the Illumina Novaseq6000 platform in 101-bp PE (paired-end) sequencing mode. Sequencing read quality was measured using the FastQC tool, and adapter sequences were removed using the cutadapt trimmer with the -e 0.1 -j 20 options. Only perfectly matched read pairs were used for further analysis. High-quality sequencing reads passed through the fastq_quality_filter (≥Q30) of the FASTX toolkit (RRID:SCR_005534).
[0151] 10. hybrid Analysis of ligand affinity and specificity
[0152] To evaluate the binding affinity of hybrid ligands to wild-type RBD and its variants, the DNA sequence of R7-02 was synthesized with a 5'-hexinyl group for hotspot peptide conjugation and 3'-FAM for flow cytometry-based binding analysis. FAM-labeled R7-02 in 1x PBSMT was thermally denatured and rapidly cooled. After thermal denaturation, R7-02 at various concentrations was challenged with RBD-coated beads while gently spinning at room temperature for 1 hour. The beads were washed twice with 1x PBSMT to exclude non-specific binding, and the bead-bound R7-02 was collected using a DynaMag-2 magnet (Invitrogen). The collected beads were resuspended in 1x PBSMT, and the mean fluorescence of the beads was measured and analyzed using CytoFLEX S (Beckman Coulter). For each measurement, 15,000 cases were analyzed. Finally, K using non-linear regression analysis (Prism software, GraphPad Prism version 9.3.1) d ...was calculated. To confirm their binding specificity, a similar characterization process was simultaneously performed on BSA-coated beads and uncoated beads (bare beads). When preparing the uncoated beads, Dynabeads M-270 carboxylic acid beads were Tris-blocked in 50 mM Tris·HCl (pH 7.4) for 15 minutes at room temperature. A similar characterization process was performed for dense sequence families (R7-01 and R7-03) and reported RBD-binding affinity reagents; Aptamer-1, CoV2-RBD-1C, CoV2-6C3, Peptide 4, P05DHu, and AM122.
[0154] 11. RBD and Molecular docking simulation of R7-02 forming a complex
[0155] To analyze the high binding affinity of R7-02 to RBD, molecular docking simulations were used to construct the molecular structure of R7-02 complexed with RBD. The crystal structures of single RBDs of the hACE2-derived hotspot peptide, LGKGDFR, and SARS-CoV-2 spike protein were obtained from the RCSB PDB database (PDB ID: 6M0J) containing single-site mutations (N501Y) of RBD. The secondary structure of the aptamer scaffold in R7-02 (Table 1) was predicted using the mfold web server and fed into RNAcomposer for 3D structure. The peptide-nucleic acid hybrid structure of R7-02 was constructed by attaching a triazole-modified linker residue between the hexinyl-modified 5' end of the folded DNA and the butanamide-modified lysine C-terminus of the hotspot peptide. Molecular docking simulations were subsequently performed to find the best fit of the hotspot peptide-binding aptamer scaffold for the RBD, while restricting the hotspot peptide and RBD to the determined locations. The resulting structure minimized energy using the AMBER14 force field utilizing the molecular dynamics simulation package OpenMM version 7.4.
[0157] 12. Reported RBD - Competitive binding using binding affinity reagents analyze
[0158] For competitive binding analysis, R7-02 and the reported RBD-binding aptamers were modified with FAM and TAMRA, respectively. Specifically, after heat denaturation and rapid cooling, they were co-incubated with 5 nM RBD beads (final volume: 100 μL) while gently rotating at room temperature for 1 hour. The beads were washed three times and resuspended in 100 μL of 1x PBSMT for analysis with CytoFLEX S (Beckman Coulter) after signal compensation. The competitive RBD-binding fraction was calculated as the ratio of the mean fluorescence intensity with competition to the mean fluorescence intensity without competition (free binding). For competitive binding with the reported RBD-binding cyclic peptides and antibodies, TAMRA-modified R7-02 was co-incubated with the FAM-modified peptide or the Alexa-488-modified RBD-antibody and analyzed in the same manner.
[0160] 13. Wild type and Omicron RBD Comparison of binding fractions between
[0161] To analyze the binding resistance of selected RBD binders (Aptamer-1, Peptide 4, P05DHu, and AM122) to SARS-CoV-2 variants, the binding fractions to wild-type and Omicron RBD were quantitatively measured at 10 nM of R7-02 and antibodies (P05DHu and AM122); and 100 nM of aptamer (Aptamer-1) and cyclic peptide (Peptide 4). After incubating RBD-coated magnetic beads with each binder at room temperature with gentle rotation for 1 hour, the beads were washed three times and resuspended in 100 μL of 1x PBSMT. The binding fractions of each binder to wild-type and Omicron RBD were measured directly using CytoFLEX S (Beckman Coulter).
[0163] 14. ELISA-based RBD - hACE2 Binding inhibition test
[0164] To characterize inhibition efficiency, the SARS-CoV-2 Inhibitor Screening Kit (ACROBiosystems) was used according to the manufacturer's protocol. Microplates were pre-coated with hACE2, and after adding various concentrations of R7-02 (1 pM–1 μM) to the plates, HRP-conjugated SARS-CoV-2 wild-type RBD was immediately added. After incubating at room temperature for 1 hour, the wells were washed three times, and substrate was added to quantify RBD-hACE2 binding. The reaction was terminated by adding a stop solution, and absorbance was measured at 450 nm using a microplate reader (Tecan). Half of the maximum inhibitory concentration (IC10) for R7-02-derived inhibition of RBD-hACE2 binding was 50 The value was determined after log-transforming the hybrid ligand concentration using sigmoid dose-response nonlinear regression analysis (Prism software, GraphPad Prism version 9.3.1). In the same way, to analyze the synergistic interaction between the hotspot peptide and the aptamer scaffold in inhibiting the RBD-hACE2 interaction, RBD-hACE2 inhibition was compared after adding 3 μM of individual ligands (LGKGDFR peptide, DNA domain of R7-02, and R7-02).
[0166] 15. Cell Culture and Sample Preparation
[0167] hACE2-293T cell lines were obtained from Takara (Japan). hACE2-293T cells were cultured in high-glucose DMEM (Sigma Aldrich) supplemented with 10% fetal bovine serum (Gibco) and 1% sodium pyruvate (Sigma Aldrich) at 37°C and 5% CO2 atmosphere. Subsequently, passages 5–15 of hACE2-293T were used for pseudotype SARS-CoV-2 neutralization assays.
[0169] 16. Pseudo Type SARS- CoV Neutralization analysis of -2
[0170] To confirm the neutralizing ability of R7-02, a neutralization assay of pseudotype SARS-CoV-2 was performed. hACE2-293T cells (~4X10 3 ) was pre-inoculated into a 96-well plate and incubated overnight. After 24 hours, 5 μL of GFP-reporting pseudotype SARS-CoV-2 (4×10 per mL) 5 Transduction units (BPS Bioscience) were pre-incubated with 3 μM R7-02 in 1x PBSM (1x PBS containing 2.5 mM magnesium) at room temperature for 30 minutes. Cell culture medium was removed from the pre-inoculated hACE2-293T cells, and the cells were washed twice with pre-warmed 1x PBSM. After washing, the mixture of pseudovirus and R7-02 was added to the cells, and the cells were incubated at 37°C for 6 hours. After infection, the 1x PBSM was replaced with fresh cell culture medium, and the cells were incubated at 37°C for an additional 48 hours. Finally, GFP fluorescence images and brightfield images were observed using a confocal microscope (Leica DMi8, source wavelength: 488 nm). The percentage of GFP-expressing infected cells relative to the total hACE2-293T cells was computationally analyzed using CellProfiler version 4.2.1. The neutralizing efficacy of other RBD-binding ligands (aptamer-1, CoV2-RBD-1C, CoV2-6C3, P05DHu, AM122, and peptide 4) was analyzed using the same method.
[0172] 17. Serum stability analysis
[0173] To characterize serum stability, nucleases were allowed to degrade FAM-labeled R7-02 in 10% fetal bovine serum at 37°C for up to 24 hours. For comparison, R7-02 with phosphothioate backbone introduction and other modifications such as 2'-O-methyl and 2'-F modifications, as well as other unmodified single-stranded DNA, were tested together. 4 μL of 10 μM samples were mixed with 10x PBS (4 μL), fetal bovine serum (4 μL), and nuclease-free water (28 μL). After incubation at 37°C for 0, 0.5, 2, 4, 8, 18, and 24 hours, 5 μL of each aliquot from the different mixtures were immediately treated at 90°C for 5 minutes and stored on ice prior to analysis. Aliquots were analyzed by electrophoresis on a 10% urea polyacrylamide gel in 1x TBE buffer, stained with 10,000x SYBR gold staining dye (Invitrogen), and imaged by an Azure C600 (Azure Biosystems).
[0175] [ Examples ]
[0176] Examples 1. Receptor-mimicking hybrid Ligand and hotspot In vitro selection of origin
[0177] Through proper folding, nucleic acids can provide a highly stable and soluble 3D scaffold capable of maintaining receptor-like binding properties by positioning hotspot peptides in the correct locations and orientations. This process is illustrated in Fig. 1a. For specific RBD-hACE2 interactions, several hotspot peptides have been reported to be approximately 30 amino acids or less in length; however, apart from the insoluble hACE2 transmembrane receptor, flexible motifs cannot strongly bind to the hotspot surface of the receptor-binding domain (RBD). Along with negligible immunogenicity, it is well known that nucleic acids are exceptionally hydrophilic due to the polar properties of the phosphate backbone. Furthermore, systematically designed repeating cycles of selection and amplification can lead to the in vitro selection of unique nucleic acids capable of structurally stabilizing hACE2-derived RBD-binding peptides. In the absence of large amounts of insoluble domains, compact and highly soluble peptide stabilizers can be administered at high doses intravenously for viral neutralization. Furthermore, the role of nucleic acids can be further extended as hotspot binding enhancers that enable cooperative interaction with target RBDs. That is, additional aptamer-like interactions may occur centered around monovalent peptide bonds, which can further enhance the hotspot binding ability of hACE2-mimicking hybrid ligands.
[0178] Numerous other nucleic acids (~10) site-specifically linked to hotspot peptides 14 In ), the hotspot peptide-supported aptamer scaffold can be separated in vitro by repeated cycles of selection and amplification. This is shown in Fig. 1b.
[0179] As shown in Fig. 1b, initially, the azide-tagged C-terminus of the peptide could be site-specifically conjugated to the 5'-hexinyl terminus of the single-stranded DNA (ssDNA) library by high-efficiency copper-catalyzed cycloaddition (Step 1 in Fig. 1b). After purification and heat denaturation, the peptide-nucleic acid hybrid library was rapidly cooled to induce unique 3D folding of the individual ssDNAs. Upon introduction of RBD-coated magnetic beads, the RBD surface attracted hotspot interactions of the hybrid ligand candidates, and magnetic separation allowed the unbound peptide-DNA conjugates to be systematically separated (Steps 2-3 in Fig. 1b). Subsequently, the DNA domains of the bead-bound hybrid ligands were selectively amplified by PCR using 5'-hexinyl-modified forward primers and 5'-phosphorylated reverse primers (Step 4 in Fig. 1b). 5'-hexinyl-modified ssDNA was generated using lambda nuclease, and a click reaction with an azide-tagged hotspot peptide again provides a pool of hybrid libraries of the same format for the next round of the evolved HOLD process (Fig. 1b, Step 5).
[0181] Examples 2. SARS- CoV -2 RBD combination hotspot peptide , and hACE2 imitator manufacturing
[0182] Among the RBD contact residues of hACE2, a seven-amino acid fragment from L351 to R357 (LGKGDFR, SEQ ID NO. 15) was selected for fusion with a random DNA library due to strong hotspot interactions with the SARS-CoV-2 RBD. Within the short, continuous chain, four amino acids (K353, G354, D355, and R357) were confirmed to be in direct contact with the RBD surface by cryo-electron microscopy (cryo-EM) observation (Fig. 2a). It is important to note that this hotspot region is associated with the binding affinity of SARS-CoV-2 VOCs (variants of concern). Due to the N501Y mutation in the RBD, VOCs bind more tightly and strongly to hACE2, which is because K353 of hACE2, the central amino acid of the selected hotspot peptide, undergoes unexpected hydrophobic interactions with the substituted tyrosine (Fig. 2b). In addition, this LGKGDFR peptide contains two hydrophobic and two positively charged amino acids, which cannot provide the properties of fully hydrophilic and negatively charged DNA. Therefore, the hotspot peptide-nucleic acid hybrid library will provide a wide variety of electrostatic interactions as it evolves to have high affinity for SARS-CoV-2's RBD.
[0183] In 7 rounds of in vitro selection with progressively increasing stringency, the hybrid ligand pool was successfully enhanced to have strong binding affinity for RBD due to the synergistic effect between the hotspot peptide and the aptamer scaffold. The results are shown in Figure 2c. Additionally, the parameters for each round of hold are shown in Table 2 below.
[0185] Round Input hybrid ligand RBD concentration Stringency condition 1 4ug(200pmol) 200nM Washing (200 uL, 3 times) 2 2ug(100pmol) 100nM Washing (200 uL, 3 times) + VDC (100x dilution, 20 min) 3 2ug(100pmol) 40nM Washing (200 uL, 3 times) + VDC (500x dilution, 30 min)+ Washing (200 uL, 3 times) 4 1ug (50 pmol) 40nM Washing (200 uL, 3 times) + VDC (500x dilution, 30 min)+ Washing (200 uL, 3 times) 5 1ug (50 pmol) 40nM Washing (200 uL, 3 times) + VDC (500x dilution, 30 min)+ Washing (200 uL, 3 times) 6 1ug (50 pmol) 40nM Washing (200 uL, 3 times) + VDC (500x dilution, 30 min, 2 times) + Washing (200 uL, 3 times) 7 1ug (50 pmol) 20nM Washing (200 uL, 3 times) + VDC (500x dilution, 30 min, 2 times) + Washing (200 uL, 3 times)
[0187] As shown in Figure 2c, the RBD binding of the hotspot peptide linkage round 7 (R7) pool was quantitatively evaluated in relative binding analysis. Despite the linkage of the hotspot peptide, the random DNA library exhibited significantly low levels of RBD binding. When the peptide-nucleic acid hybrid library (Hybrid random library) was challenged with RBD-coated magnetic beads, the binding fraction was only 0.38%, indicating that the hotspot peptide cannot bind strongly to the RBD without a stable scaffold. In the absence of the LGKGDFR peptide, the R7 pool showed a slight increase in RBD binding, exhibiting a binding fraction of 5.74%, which is presumed to be due to the self-aptamer binding effect. On the other hand, the peptide-supported R7 pool dramatically improved its affinity for RBD, and its binding fraction (22.6%) increased by 59.37-fold and 3.94-fold compared to the random DNA-peptide conjugate and the peptide-deficient R7 pool, respectively. This significant improvement in RBD binding is due to synergistic interactions between the hotspot peptide and the newly evolved aptamer scaffold.
[0189] Examples 3. peptide -support Aptamer scaffold's Identification and Characterization
[0190] The optimal peptide-supported aptamer scaffolds were identified in the R7 hybrid ligand pool using high-throughput sequencing and flow cytometry-based binding analysis. When over 4 million DNA sequences were sequenced in the R7 pool, the three most abundant sequence families were found to account for a high occupancy rate (>18%). This is shown in Table 3 below (Sequence Nos. 16 to 22). Among the three sequence families, the most representative DNA sequences were synthesized with 5'-hexinyl groups for site-specific peptide binding and 3'-FAM dyes for flow cytometry-based binding analysis. For 5'-linked hotspot peptides, the second most abundant DNA sequence (the DNA domain of R7-02) exhibited the strongest RBD binding. In relative binding analysis, the RBD binding fraction of R7-02 was approximately 5-fold and 8-fold greater than that of R7-01 and R7-03, respectively (Fig. 3a).
[0192] Copy rank Sequences (5'→3') Sequence number Number of sequences Percentage of the sequence family 1 CTCCACAACCGCTGATCGACGCAGATCTTGTGGGT 16 483,860 14.416 % CTCCACAACCGCTGATCGACGCAGATCTTGTGTGGT 17 16,249 2 ACGCAATCGTGGGGTTGGGGATATAATGGTA 18 35,997 1.834 % ACGCAATCGTGGGGTTGGGGACATAATGGTA 19 13,909 ACGCAATCGTGGGTTGGGATATAATGGTA 20 13,703 3 CACACCAAATCTGAGTCTACCCCATGAAGG 21 30,943 1.769 % CACACCAAATCTGAGTCTACCCTATGAAGG 22 30,433
[0194] To act as an hACE2 mimic, R7-02, the most potent hybrid ligand, exhibited high affinity and specificity for RBD at the correct binding site for hACE2. The K of R7-02 d When measured quantitatively, it was 5.702 nM for RBD (Fig. 3b, green), and K of R7-01 (27.01 nM) and R7-03 (93.8 nM). d The value was much higher than R7-02 (Fig. 3c).
[0195] In addition, molecular docking simulations were performed, and the results are shown in Fig. 3d.
[0196] As shown in Fig. 3d, it was predicted that the high binding affinity of R7-02 to RBD actually influences the cooperative binding effect. In the energy minimization simulation snapshot, the LGKGDFR peptide (red) is precisely located at the binding hotspot of the original hACE2 (white) and RBD (blue), and the binding is effectively stabilized by the conjugated aptamer scaffold (green). DNA folding at the 3' end provides an additional binding motif to the loop structure (A475-N487) (yellow arrow) of RBD, inducing strong and specific binding of R7-02 to RBD. The precise location of R7-02 at the interface between RBD and hACE2 demonstrates the potential for SARS-CoV-2 neutralization at low nanomolar concentrations in physiological body fluids.
[0197] R7-02 exhibited sustained, maintained binding to the target surface of RBD even in competition with previously known RBD binding affinity reagents (Figs. 3e and 3f). To induce RBD binding competition, hybrid ligands of hotspot peptides and aptamer scaffolds were co-incubated with RBD-binding nucleic acid aptamers (CoV2-RBD-1C, CoV2-6C3, Aptamer-1), macrocyclic peptides (Peptide 4), or monoclonal antibodies (P05DHu and AM122). Most of these are known to block the binding interface between RBD and hACE2 (Fig. 3e). Additionally, K of various RBD binders against R7-02 under the same conditions d The value was checked (Fig. 3g).
[0198] To evaluate competitive binding, the RBD binding fraction of R7-02 with and without potential binding competitors was measured, and the reduction in RBD binding was quantitatively compared with the reduction of other affinity reagents (Fig. 3f). Even after co-incubation with RBD-binding aptamers or cyclic peptides for 1 hour, R7-02 was able to maintain RBD binding, and the ratio of competitive binding to free binding decreased to a low level (approx. 6.8%). Meanwhile, RBD binding of all other aptamers and cyclic peptides was significantly inhibited, with the ratio between competitive binding and free binding decreasing by up to 77.2%, which implies that the binding of monomeric aptamers and cyclic peptides is relatively weak in occupying restricted RBD binding sites against competition with cooperative hybrid ligands. Furthermore, due to different binding sites, competition between R7-02 and the P05DHu and AM122 antibodies was insignificant.
[0200] Examples 4. SARS- CoV -2 VOC (variants of concern) Korea hACE2 imitation Binding resistance
[0201] The hotspot peptide-nucleic acid hybrid molecule (R7-02) was confirmed to bind strongly to all reported VOCs of SARS-CoV-2 due to its high variant tolerance in binding. Although it initially evolved to bind to wild-type RBDs via a hold process, the binding capability of the hybrid ligand enables the recognition of highly mutated RBDs by VOCs. This allows for strong interaction with the hotspot interface of the RBDs. It was found that the VOCs possess several key mutations, including N501Y which interacts highly with the lysine of the LGKGDFR peptide in the hybrid ligand, thereby enhancing binding to the hACE2 receptor and delivery to host cells (Fig. 4a).
[0202] When the binding of R7-02 to five VOCs was quantitatively evaluated, the K of R7-02 d The values (alpha, beta, gamma, delta, and omicron; 5.486 nM, 3.376 nM, 1.614 nM, 2.757 nM, and 1.209 nM) were lower than those of wild-type RBD (5.702 nM), confirming the binding resistance of R7-02 to all variants (Fig. 4b). Interestingly, Omicron, which has the most RBD mutations, was most strongly recognized by R7-02, whereas several selected types of RBD binders (Aptamer-1, Peptide 4, P05DHu, and AM122) lost their RBD binding ability due to severe mutations (Figs. 4c and 4d).
[0203] Through this, it was confirmed that R7-02 has significantly superior binding resistance to SARS-CoV-2 VOCs. Furthermore, this implies that the binding of hotspot peptide-derived RBD may be influenced by an improved hACE2 recognition mechanism by SARS-CoV-2 VOCs.
[0205] Examples 5. RBD - hACE2 Interaction inhibition and Pseudo Type SARS- CoV -2 neutralization
[0206] Due to strong binding to RBD, the hotspot peptide-nucleic acid hybrid molecule efficiently inhibited the interaction between SARS-CoV-2 RBD and the hACE2 receptor even at nanomolar concentrations. To characterize the inhibition efficiency, an enzyme-linked immunosorbent assay (ELISA) was performed while varying the concentration of R7-02 from 1 pM to 1 μM, and R7-02 inhibited RBD-hACE2 binding at a half-maximal inhibitory concentration (IC10) of 138.9 nM. 50 ) was shown (Fig. 5a).
[0207] Meanwhile, RBD inhibition by R7-02 was guided by the synergistic effect of the systematically coupled hotspot peptide and the in vitro evolved aptamer scaffold; the individual components of R7-02, the LGKGDFR peptide and the aptamer scaffold, showed RBD-hACE2 interaction inhibition rates of 11.69% and 26.82%, respectively, at a concentration of 3 μM, whereas the entire structure of R7-02 showed an inhibition rate of 89.60%. As evidence of aptameric behavior, the DNA scaffold alone experimental group showed better inhibition efficiency compared to the random DNA library (inhibition rate 3.77%) (Fig. 5b).
[0208] Previously, several RBD-binding affinity reagents could not effectively inhibit RBD-hACE2 interactions because they were unable to block the precise hACE2 contact residues on the RBD surface. In contrast, the hotspot-derived RBD binding of R7-02 demonstrated efficient inhibition of RBD at hACE2 binding, showing great potential for SARS-CoV-2 neutralization.
[0209] Accordingly, the SARS-CoV-2 neutralizing ability of the hotspot peptide-nucleic acid hybrid molecule was further confirmed. For neutralization analysis, pseudotype SARS-CoV-2 was prepared that expresses both the SARS-CoV-2 spike protein and green fluorescent protein (GFP) but lacks self-replication function. The neutralization efficiency of R7-02 was analyzed fluorescence by measuring the fluorescence intensity of GFP, which is expressed only in cells infected by pseudotype SARS-CoV-2 (Fig. 5c). Briefly, hACE2-overexpressing HEK-293T cell lines (hACE2-293T) were pre-inoculated into microplates overnight and challenged with pseudotype SARS-CoV-2 (0.5 multiple infection, MOI) for 6 hours for viral infection. The results are shown in Figs. 5d and 5e.
[0210] As shown in Figures 5d and 5e, in the absence of an RBD inhibitor, hACE2-293T was infected with pseudotype SARS-CoV-2, and quantitatively, 58.4% of the total cells emitted strong green fluorescence as evidence of successful viral infection. Meanwhile, in the presence of the hotspot peptide or aptamer scaffold constituting R7-02, the level of RBD binding was limited, and the infection rate of pseudotype SARS-CoV-2 decreased to 22.0% and 12.6%, respectively. Additionally, R7-02, a hotspot peptide-supported aptamer scaffold, showed negligible green fluorescence and a significantly lower percentage of infected cells (1.9%).
[0211] Compared to the viral infection rates of many different RBD binders, the viral infection rate of R7-02 was found to be significantly lower or similar (Figs. 5f and 5g). Meanwhile, it should be considered that, unlike most commonly used neutralizing antibodies, the hybrid ligand of the present invention is entirely synthetic. That is, the present invention has a low molecular weight (20 kDa), which is one-tenth the level of monoclonal antibodies, yet demonstrates an effect of efficient infection inhibition. Furthermore, without additional modifications, the chimeric structure of the peptide-aptamer hybrid ligand showed good nuclease resistance and serum stability compared to well-known oligonucleotide modifications (e.g., phosphorothioate backbone, 2'-O-methyl and 2'-F modifications) (Fig. 5h), indicating great potential as a SARS-CoV-2 neutralizing agent.
[0213] The foregoing description of the present invention is for illustrative purposes only, and those skilled in the art will understand that other specific forms can be easily modified without altering the technical spirit or essential features of the present invention. Therefore, the embodiments described above should be understood as illustrative in all respects and not restrictive.
Claims
Claim 1 A composition for preventing or treating coronavirus infection comprising a peptide-nucleic acid hybrid molecule, wherein the peptide is a hotspot-derived peptide having the amino acid sequence of SEQ ID NO. 15, the coronavirus is any one variant selected from the group consisting of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) or its alpha (α), beta (β), gamma (γ), delta (δ), and omicron (Ο) variants, and the nucleic acid comprises the nucleotide sequence of SEQ ID NO.
18. Claim 2 A composition according to claim 1, characterized in that the peptide-nucleic acid hybrid molecule is prepared through the following method: (a) a step of preparing a peptide-nucleic acid hybrid by site-specifically binding a hotspot-derived peptide consisting of the amino acid sequence of SEQ ID NO. 15 and a random nucleic acid library; (b) a step of mixing and culturing the peptide-nucleic acid hybrid of step (a) with magnetic beads coated with a target protein; and (c) a step of selecting a peptide-nucleic acid hybrid molecule that binds to the target protein using a magnet. Claim 3 In paragraph 2, the composition is characterized by further comprising the following steps: (d) a step of selectively amplifying and replicating the nucleic acid portion of the peptide-nucleic acid hybrid molecule selected in step (c); (e) a step of purifying the double-stranded DNA produced in step (d) by preparing it into single-stranded DNA using a nuclease; and (f) a step of preparing a new random nucleic acid library composed of the single-stranded DNA of step (e) and repeating the selection, amplification, and purification processes of steps (a) to (f). Claim 4 A composition according to claim 1, characterized in that the peptide-nucleic acid hybrid molecule binds to the receptor binding domain (RBD) of the spike protein of the coronavirus. Claim 5 A composition according to claim 4, characterized in that the RBD is a wild type or a mutant type. Claim 6 A composition according to claim 5, characterized in that the above mutation comprises one or more selected from the group consisting of N501Y, E484K, K417N, K417T, T478K, L452R, E484A, G339D, S371L, S373P, S375F, N440K, S477N, G446S, Q493R, G496S, Q498R, and Y505H. Claim 7 A composition according to claim 1, wherein the peptide-nucleic acid hybrid molecule neutralizes the coronavirus. Claim 8 A composition according to claim 1, characterized in that the peptide-nucleic acid hybrid molecule inhibits the interaction between the RBD of the coronavirus and the hACE2 (human angiotensin-converting enzyme 2) receptor. Claim 9 A composition according to claim 1, wherein the nucleic acid increases the binding affinity and water solubility of the RBD of the coronavirus spike protein. Claim 10 A composition according to claim 1, wherein the peptide-nucleic acid hybrid molecule satisfies any one of the following characteristics: (a) nuclease resistance; and (b) serum stability. Claim 11 A composition according to claim 1, wherein the peptide-nucleic acid hybrid molecule is for intravenous or respiratory administration. Claim 12 delete Claim 13 A composition for the prevention or treatment of coronavirus infection comprising a peptide-nucleic acid hybrid molecule prepared by a method including the following steps, wherein the coronavirus is any one variant selected from the group consisting of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) or its alpha (α), beta (β), gamma (γ), delta (δ), and omicron (Ο) variants: (a) a step of preparing a peptide-nucleic acid hybrid by site-specific binding of a hotspot-derived peptide having the amino acid sequence of SEQ ID NO. 15 and a random nucleic acid library; (b) a step of mixing and culturing the peptide-nucleic acid hybrid of step (a) with magnetic beads coated with a target protein; and (c) a step of selecting a peptide-nucleic acid hybrid molecule that binds to the target protein using a magnet. Claim 14 In claim 13, the above method is characterized by further comprising the following steps: (d) a step of selectively amplifying and replicating the nucleic acid portion of the peptide-nucleic acid hybrid molecule selected in step (c); (e) a step of purifying the double-stranded DNA produced in step (d) by preparing it into single-stranded DNA using a nuclease; and (f) a step of preparing a new random nucleic acid library composed of the single-stranded DNA of step (e) and repeating the selection, amplification, and purification processes of steps (a) to (f). Claim 15 A composition according to claim 13, wherein the method further comprises, after step (a), a step of heat-denaturing and cooling the peptide-nucleic acid hybrid to induce 3D folding of the nucleic acid. Claim 16 A composition according to claim 13, wherein the hotspot-derived peptide of step (a) is a peptide having one or more functional groups selected from the group consisting of azido-lysine, azidobutanoic acid, azidoacetic acid, and azide attached to the C-terminus or N-terminus, and the random nucleic acid library of step (a) comprises a single-stranded nucleic acid having one or more functional groups selected from the group consisting of hexynyl, 5-octadiynyl, and alkyne attached to the 5'-terminus, and wherein the hotspot-derived peptide and the single-stranded nucleic acid are site-specifically bound by a click reaction. Claim 17 A composition according to claim 13, wherein the hotspot-derived peptide of step (a) is a peptide having one or more functional groups selected from the group consisting of hexynyl, 5-octadiynyl, and alkyne attached to the C-terminus or N-terminus, and the random nucleic acid library of step (a) comprises a single-stranded nucleic acid having one or more functional groups selected from the group consisting of azido-lysine, azidobutanoic acid, azidoacetic acid, and azide attached to the 5'-terminus, and wherein the hotspot-derived peptide and the single-stranded nucleic acid are site-specifically bound by a click reaction. Claim 18 In claim 13, the composition is characterized in that the random nucleic acid library has the following structure: 5'-functional group-forward primer-[N x ] -Reverse primer-3', the functional group is selected from the group consisting of hexynyl, 5-octadiynyl, alkyne, azido lysine, azidobutanoic acid, azidoacetic acid, and azide, wherein N is A, T, C, or G, and x is an integer from 25 to 100. Claim 19 A quasi-drug composition for preventing or inhibiting coronavirus infection comprising a peptide-nucleic acid hybrid molecule, wherein the peptide is a hotspot-derived peptide consisting of the amino acid sequence of SEQ ID NO. 15, the coronavirus is any one variant selected from the group consisting of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) or its alpha (α), beta (β), gamma (γ), delta (δ), and omicron (Ο) variants, and the nucleic acid comprises the nucleotide sequence of SEQ ID NO.
18. Claim 20 An antiviral composition for coronavirus comprising a peptide-nucleic acid hybrid molecule, wherein the peptide is a hotspot-derived peptide having the amino acid sequence of SEQ ID NO. 15, the coronavirus is any one variant selected from the group consisting of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) or its alpha (α), beta (β), gamma (γ), delta (δ), and omicron (Ο) variants, and the nucleic acid comprises the nucleotide sequence of SEQ ID NO.
18. Claim 21 A composition for neutralizing a coronavirus comprising a peptide-nucleic acid hybrid molecule, wherein the peptide is a hotspot-derived peptide having the amino acid sequence of SEQ ID NO. 15, the coronavirus is any one variant selected from the group consisting of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) or its alpha (α), beta (β), gamma (γ), delta (δ), and omicron (Ο) variants, and the nucleic acid comprises the nucleotide sequence of SEQ ID NO. 18.
Citation Information
Patent Citations
Peptides having protease activity for use in the treatment or prevention of coronavirus infections
KR1020200107958A
